Samsara BioCapital GP, LLC - 14 Nov 2023 Form 4 Insider Report for CARGO Therapeutics, Inc. (CRGX)

Reporting relationship: 10%+ Owner
Issuer ticker: CRGX
Reported as of: 14 Nov 2023
Net transaction value: +$9,999,990
SEC form: 4
Accepted by SEC: 16 Nov 2023, 19:39:55 UTC
Prior SEC filing: 09 Nov 2023
Next SEC filing: 14 Feb 2024
Source filing: View source filing
Reporting owner signature: Samsara BioCapital GP, LLC, By /s/ Srinivas Akkaraju, Managing Member

Key filing fact

Samsara BioCapital GP, LLC filed Form 4 for CARGO Therapeutics, Inc. (CRGX) on 16 Nov 2023.

Key facts

This page summarizes Samsara BioCapital GP, LLC's Form 4 filing for CARGO Therapeutics, Inc. (CRGX).
5 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 16 Nov 2023, 19:39.

Change

Previous filing in this sequence was filed on 09 Nov 2023.
Current net transaction value: +$9,999,990.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRGX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +3,381,323
Change %: +4588%
Price
Shares after: 3,455,023
Date: 14 Nov 2023
Ownership: By Samsara BioCapital, L.P.
Footnotes: F1, F2

CRGX transaction

Common Stock

Purchase

Transaction value: $9,999,990
Shares: +666,666
Change %: +19%
Price: $15.00
Shares after: 4,121,689
Date: 14 Nov 2023
Ownership: By Samsara BioCapital, L.P.
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRGX transaction Derivative

Series Seed convertible preferred stock

Conversion of derivative security

Transaction value: $0
Shares: -663,300
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 14 Nov 2023
Ownership: By Samsara BioCapital, L.P.
Underlying class: Common Stock
Underlying amount: 663,300
Exercise price
Footnotes: F1, F2

CRGX transaction Derivative

Series A-1 convertible preferred stock

Conversion of derivative security

Transaction value: $0
Shares: -884,400
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 14 Nov 2023
Ownership: By Samsara BioCapital, L.P.
Underlying class: Common Stock
Underlying amount: 884,400
Exercise price
Footnotes: F1, F2

CRGX transaction Derivative

Series A-2 convertible preferred stock

Conversion of derivative security

Transaction value: $0
Shares: -1,833,623
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 14 Nov 2023
Ownership: By Samsara BioCapital, L.P.
Underlying class: Common Stock
Underlying amount: 1,833,623
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each share of Series Seed convertible preferred stock, Series A-1 convertible preferred stock and Series A-2 convertible preferred stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date.

Footnote F2

Shares are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.